Abstract
Summary: Three children in two families presented in early childhood with episodes of illness associated with fasting which resembled Reye's syndrome: coma, hypoglycemia, hyperammonemia, and fatty liver. One child died with cerebral edema during an episode. Clinical studies revealed an absence of ketosis on fasting (plasma beta-hydroxybutyrate < 0.4 mmole/liter) despite elevated levels of free fatty acids (2.6–4.2 mmole/liter) which suggested that hepatic fatty acid oxidation was impaired. Urinary dicarboxylic acids were elevated during illness or fasting. Total carnitine levels were low in plasma (18–25 μmole/liter), liver (200–500 nmole/g), and muscle (500–800 nmole/g); however, treatment with L-carnitine failed to correct the defect in ketogenesis. Studies on ketone production from fatty acid substrates by liver tissue in vitro showed normal rates from short-chain fatty acids, but very low rates from all medium and long-chain fatty acid substrates. These results suggested that the defect was in the mid-portion of the intramitochondrial beta-oxidation pathway at the medium- chain acyl-CoA dehydrogenase step. A new assay for the electron transfer flavoprotein-linked acyl-CoA dehydrogenases was used to test this hypothesis. This assay follows the decrease in electron transfer flavoprotein fluorescence as it is reduced by acyl-CoA-acyl-CoA dehydrogenase complex. Results with octanoyl-CoA as substrate indicated that patients had less than 2.5% normal activity of medium-chain acyl-CoA dehydrogenase. The activities of short-chain and isovaleryl acyl-CoA dehydrogenases were normal; the activity of long-chain acyl-CoA dehydrogenase was one-third normal.
These results define a previously unrecognized inherited metabolic disorder of fatty acid oxidation due to deficiency of medium-chain acyl-CoA dehydrogenase. The carnitine deficiency in these patients appears to be a secondary consequence of their defect in fatty acid oxidation. It is possible that other patients with “systemic carnitine deficiency,” who fail to respond to carnitine therapy, may also have defects in fatty acid oxidation similar to medium-chain acyl-CoA dehydrogenase deficiency.
Similar content being viewed by others
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Stanley, C., Hale, D., Coates, P. et al. Medium-Chain Acyl-CoA Dehydrogenase Deficiency in Children with Non-Ketotic Hypoglycemia and Low Carnitine Levels. Pediatr Res 17, 877–884 (1983). https://doi.org/10.1203/00006450-198311000-00008
Issue Date:
DOI: https://doi.org/10.1203/00006450-198311000-00008
This article is cited by
-
Carnitine supplementation attenuates myocardial lipid accumulation in long‐chain acyl‐CoA dehydrogenase knockout mice
Journal of Inherited Metabolic Disease (2013)
-
The enzymology of mitochondrial fatty acid beta‐oxidation and its application to follow‐up analysis of positive neonatal screening results
Journal of Inherited Metabolic Disease (2010)
-
The clinical manifestation of MCAD deficiency: challenges towards adulthood in the screened population
Journal of Inherited Metabolic Disease (2010)
-
Adult presentations of medium‐chain acyl‐CoA dehydrogenase deficiency (MCADD)
Journal of Inherited Metabolic Disease (2009)
-
Mitochondrial fatty acid oxidation defects—remaining challenges
Journal of Inherited Metabolic Disease (2008)